ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Summary of societal recommendations on genetic assessment in women with ovarian and uterine cancers

Summary of societal recommendations on genetic assessment in women with ovarian and uterine cancers
Stakeholder Date(s) issued Ovarian cancer recommendations Uterine cancer recommendations
Society of Gynecologic Oncology (SGO) 2014 Genetic counseling and testing for all ovarian, fallopian tube, peritoneal cancers[1] Joint ACOG/SGO recommendations: Tumor testing for MSI/MMR IHC on any endometrial or colorectal tumor from a woman at risk for Lynch syndrome by focused personal and family medical history, or all endometrial cancers age <60. Germline testing for marker expression loss on tumor tissue.[4]
  • Endometrial cancer age <50
  • Endometrial cancer dx at age ≥50 if there is a FDR with colorectal or endometrial cancer at any age
  • Synchronous or metachronous colorectal or endometrial cancer in the same person
  • Endometrial cancer showing mismatch repair deficiency on tumor screening
  • Endometrial cancer and 2 additional cases of any LS-associated cancer in the same person or in close relatives
  • Epithelial endometrial cancer and 2 additional Cowden syndrome criteria in the same person[3]
American College of Obstetricians and Gynecologists (ACOG) 2009 Patients with greater than an approximate 20 to 25% chance of having a mutation[2]
National Society of Genetic Counselors (NSGC) [Joint with the American College of Medical Genetics and Genomics (ACMG)] 2014 Single case of ovarian, fallopian tube, or peritoneal cancer present in the patient or a first-degree relative[3]
MSI: microsatellite instability; MMR: mismatch repair; IHC: immunohistochemical testing; dx: diagnosed; FDR: first-degree relative.
References:
  1. SGO Position Statement, Genetic testing for gynecologic cancer, October 2014. Available at: https://www.sgo.org/newsroom/position-statements-2/genetic-testing-for-gynecologic-cancer/ (Accessed on January 18, 2018).
  2. McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: An NRG oncology/Gynecologic Oncology Group study. J Clin Oncol 2016; 34:3062.
  3. Meyer LE, Anderson RA, Lacour A, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: Missed opportunities. Obstet Gynecol 2010; 115:945.
  4. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261.
Reproduced from: Randall LM, Pothuri B, Swisher EM, et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol 2017; 146:217. Table used with the permission of Elsevier Inc. All rights reserved.
Graphic 116335 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟